Product Pathways
Products
BCP0019 AZD0530
The effect of AZD0530, a dually active inhibitor of c-Src and Bcr-ABL, on bone resorption, has been tested in a Phase I clinical trials with promising results.
BCP0099 Danusertib(PHA-739358)
Danusertib (PHA-739358) is an Aurora inhibitor for Aurora A/B/C, Bcr-Abl, c-RET and FGFR with IC50 of 13 nM/79 nM/61 nM, 25 nM, 31 nM and 47 nM, respectively.
BCP0033 Bosutinib
Inhibitors of SRC, ABL and TEC family kinases.
BCP0048 Dasatinib
Dasatinib (BMS-354825, Sprycel) is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.5 nM and 79 nM, respectively.
BCP0058 FTY720
FTY720 (Fingolimod, Gilenya) is a S1P antagonist.
BCP0079 Nilotinib
Nilotinib, a novel, selective BCR-ABL inhibitor.
BCP0234 Imatinib mesylate
Imatinib Mesylate is orally bioavailability mesylate salt of Imatinib, which is a multi-target inhibitor of v-Abl, c-Kit and PDGFR , respectively.
BCP0413 Bafetinib(INNO-406)
Bafetinib (INNO-406) is an orally available, dual Abl/Lyn kinase inhibitor that is up to 55-times more potent than imatinib in Bcr-Abl cell lines.
BCP0536 Dasatinib monohydrate
Dasatinib (BMS-354825, Sprycel) is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.5 nM and 79 nM, respectively.
BCP000618 PD173955
PD173955 is an ATP-competitive, dual Src/Abl kinase inhibitor.
第一页 1 2 最后页 
 
Only for research purpose , not for human consumption Copyright©2012 ShangHai Biochempartner Co.,Ltd.